B244
Atopic Dermatitis
Key Facts
About AOBiome
AOBiome is a private, clinical-stage biotech leveraging a single strain of ammonia-oxidizing bacteria (AOB) as a therapeutic platform to treat inflammatory skin diseases. Its lead program, B244, is in Phase 3 for atopic dermatitis, with additional Phase 2 programs in acne, eczema, and rosacea. The company's core thesis is that reintroducing this evolutionarily lost bacterium can restore immune functionality, offering a novel mechanism that simultaneously downregulates multiple inflammatory pathways implicated in itch and inflammation.
View full company profileAbout AOBiome
AOBiome is a private, clinical-stage biotech leveraging a single strain of ammonia-oxidizing bacteria (AOB) as a therapeutic platform to treat inflammatory skin diseases. Its lead program, B244, is in Phase 3 for atopic dermatitis, with additional Phase 2 programs in acne, eczema, and rosacea. The company's core thesis is that reintroducing this evolutionarily lost bacterium can restore immune functionality, offering a novel mechanism that simultaneously downregulates multiple inflammatory pathways implicated in itch and inflammation.
View full company profileAbout AOBiome
AOBiome is a private, clinical-stage biotech leveraging a single strain of ammonia-oxidizing bacteria (AOB) as a therapeutic platform to treat inflammatory skin diseases. Its lead program, B244, is in Phase 3 for atopic dermatitis, with additional Phase 2 programs in acne, eczema, and rosacea. The company's core thesis is that reintroducing this evolutionarily lost bacterium can restore immune functionality, offering a novel mechanism that simultaneously downregulates multiple inflammatory pathways implicated in itch and inflammation.
View full company profileAbout AOBiome
AOBiome is a private, clinical-stage biotech leveraging a single strain of ammonia-oxidizing bacteria (AOB) as a therapeutic platform to treat inflammatory skin diseases. Its lead program, B244, is in Phase 3 for atopic dermatitis, with additional Phase 2 programs in acne, eczema, and rosacea. The company's core thesis is that reintroducing this evolutionarily lost bacterium can restore immune functionality, offering a novel mechanism that simultaneously downregulates multiple inflammatory pathways implicated in itch and inflammation.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |
| AX-158 | Artax Biopharma | Phase 2 |